GlassScriptPhysician profile
Azriel Hirschfeld
NPI 1043240336
$30,923.68
in general payments reported to CMS, 2019-2025
65 companies · $1,711 in 2025
The $1,711 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $3,963 · 2021: $4,705 · 2022: $4,225 · 2023: $2,387 · 2024: $2,853 · 2025: $1,711.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,423 · Long Term Medical Supply Or Device Loan: $1,299 · Education: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,422.56 |
| Long Term Medical Supply Or Device Loan | $1,299.06 |
| Education | $229.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $9,292.95 | 2019-2025 | Enhertu, Lynparza, Imfinzi |
| Exelixis INC. | $3,703.23 | 2019-2025 | Cabometyx |
| Novartis Pharmaceuticals Corporation | $3,635.87 | 2019-2025 | |
| Pfizer INC. | $1,230.33 | 2019-2025 | |
| Lilly USA, LLC | $1,080.30 | 2019-2025 | Verzenio, Retevmo, Jaypirca |
| Eisai INC. | $980.13 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $830.50 | 2019-2024 | Keytruda, Welireg, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $777.18 | 2019-2025 | Opdivo, Reblozyl |
| Janssen Biotech, INC. | $702.51 | 2019-2025 | Erleada, Balversa, Akeega |
| Amgen INC. | $691.70 | 2020-2023 | Xgeva, Vectibix, Lumakras |
| Seagen INC. | $686.55 | 2019-2023 | Tukysa, Adcetris |
| Incyte Corporation | $631.08 | 2020-2022 | |
| Glaxosmithkline, LLC. | $474.58 | 2021-2025 | Zejula, Jemperli |
| Rigel Pharmaceuticals, INC. | $396.58 | 2019-2022 | |
| Menarini Silicon Biosystems, INC. | $384.41 | 2023-2025 | Cellsearch |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Azriel Hirschfeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.